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Abstract
Background: In humans, overproduction of apolipoprotein B (apoB) is positively associated with
premature coronary artery diseases. To reduce the levels of apoB mRNA, we have designed an
apoB mRNA-specific hammerhead ribozyme targeted at nucleotide sequences GUA6679 (RB15)
mediated by adenovirus, which efficiently cleaves and decreases apoB mRNA by 80% in mouse liver
and attenuates the hyperlipidemic condition. In the current study, we used an adeno-associated
virus vector, serotype 2 (AAV2) and a self-complementary AAV2 vector (scAAV2) to demonstrate
the effect of long-term tissue-specific gene expression of RB15 on the regulation apoB mRNA in
vivo.
Methods: We constructed a hammerhead ribozyme RB15 driven by a liver-specific transthyretin
(TTR) promoter using an AAV2 vector (rAAV2-TTR-RB15). HepG2 cells and hyperlipidemic mice
deficient in both the low density lipoprotein receptor and the apoB mRNA editing enzyme genes
(LDLR-/-Apobec1-/-; LDb) were transduced with rAAV2-TTR-RB15 and a control vector rAAV-TTR-
RB15-mutant (inactive ribozyme). The effects o f  r i b o z y m e  R B 1 5  o n  a p o B  m e t a b o l i s m  a n d
atherosclerosis development were determined in LDb mice at 5-month after transduction. A self-
complementary AAV2 vector expressing ribozyme RB15 (scAAV2-TTR-RB15) was also engineered
and used to transduce HepG2 cells. Studies were designed to compare the gene expression
efficiency between rAAV2-TTR-RB15 and scAAV2-TTR-RB15.
Results: The effect of ribozyme RB15 RNA on reducing apoB mRNA levels in HepG2 cells was
observed only on day-7 after rAAV2-TTR-RB15 transduction. And, at 5-month after rAAV2-TTR-
RB15 treatment, the apoB mRNA levels in LDb mice were significantly decreased by 43%, compared
to LDb mice treated with control vector rAAV2-TTR-RB15-mutant. Moreover, both the rAAV2-
TTR-RB15 viral DNA and ribozyme RB15 RNA were still detectable in mice livers at 5-month after
treatment. However, this rAAV2-TTR-RB15 vector mediated a prolonged but low level of
ribozyme RB15 gene expression in the mice livers, which did not produce the therapeutic effects
on alteration the lipid levels or the inhibition of atherosclerosis development. In contrast, the
ribozyme RB15 RNA mediated by scAAV2-TTR-RB15 vector was expressed immediately at day-1
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after transduction in HepG2 cells. The apoB mRNA levels were decreased 47% (p = 0.001),
compared to the control vector scAAV2-TTR-RB15-mutant.
Conclusion:  This study provided evidence that the rAAV2 single-strand vector mediated a
prolonged but not efficient transduction in mouse liver. However, the scAAV2 double-strand
vector mediated a rapid and efficient gene expression in liver cells. This strategy using scAAV2
vectors represents a better approach to express small molecules such as ribozyme.
Background
Ribozymes are small RNA molecules with enzymatic
RNA-cleaving activity [1]. Our laboratory [2,3] has previ-
ously demonstrated that adenovirus mediated apolipo-
protein B (apoB) mRNA-specific hammerhead ribozyme
cleaved apoB mRNA efficiently. In the dyslipidemic
mouse model, the effect of decreased apoB mRNA results
in a marked decrease in plasma cholesterol, triglyceride
and apo B levels [3] and these hypolipidemic effects per-
sist to day-21. To assess the utility of this approach in
treating hyperlipidemia, it is essential to explore other
gene delivery vectors for prolonged gene expression. We
sought to use adeno-associated viruses (AAV) for the lon-
gevity of transgene expression [4]. Furthermore, the AAV
vector does not elicit T cells immune responses to the
transgene product, because it is believed that AAV does
not infect antigen-presenting cells [5]. These features sug-
gest that AAV is a better vector for somatic gene transfer.
To decrease apoB mRNA expression, we have designed a
hammerhead ribozyme targeted at GUA6679  of apoB
mRNA (RB15) to cleave apoB mRNA [2,3]. In this study,
we constructed the apolipoprotein B mRNA-specific ham-
merhead ribozyme (RB15) driven by a liver-specific tran-
sthyretin (TTR) promoter [6] using the AAV2 serotype
virus vector (rAAV2-TTR-RB15). We delivered rAAV2-TTR-
RB15 to an atherosclerosis-susceptible mouse model,
which is deficient in both the low density lipoprotein
receptor (LDLR-/-) and the apoB mRNA editing enzyme
(Apobec1-/-) genes [7-9], to evaluate the duration of gene
expression by the AAV2 vector and the effect of apoB
mRNA-specific hammerhead ribozymes on apoB mRNA
gene expression. An improved strategy using self-comple-
mentary AAV2 vector shows rapid and efficient gene
expression in HepG2 cells.
Methods
Construction and production of the AAV2 plasmid vectors
pAAV2-TTR-RB15 plasmid vectors
We chose transthyretin (TTR, kindly provided by Dr. Terry
Van Dyke at the University of North Carolina, Chapel
Hill, NC) as the liver-specific promoter. The enhancer/
promoter region TTR has been shown to target transgene
expression specifically to the liver [6,10]. We have previ-
ously shown that hammerhead ribozyme targeted specifi-
cally at apoB mRNA sequences of GUA6679↓ (RB15)
cleaves apoB mRNA efficiently [2,3]. A point mutation of
the conserved catalytic domain of ribozyme at nucleotide
G5 → A (G5A) of RB15 completely abolished the catalytic
activity (designated as RB15-mutant). RB15 or RB15-
mutant driven by TTR promoter was cloned into plasmid
pZAC2.0 (kindly provided by Dr. Alan Davis at Baylor
College of Medicine, Houston, TX) flanking by the
inverted terminal repeats of AAV2. A 1931-bp human
genomic fragment of hypoxanthine guanine phosphorri-
bosyltransferase (HPRT) as the stuffer sequences was
inserted downstream of 5' ITR at the SspB1 site of
pZAC2.0 to maintain the wild-type AAV genome size. The
shuttle vectors were designated as pAAV2-TTR-RB15,
pAAV2-TTR-RB15-mutant, which contains the viral
genomic size of 3967-bp. The nucleotide sequences were
confirmed by sequencing. As noted, this viral genomic
size was suboptimal; the packaging limit of AAV size is 5
kb and a genome of 4.5 kb is the optimal size [11].
Self-complementary recombinant AAV2 vector (scAAV2)
To construct scAAV2-TTR-RB15 and -RB15-mutant vec-
tors, we deleted ~1479-bp of the stuffer sequences from
pAAV2-TTR-RB15 and -RB15 mutant to generate a small
size clone of 2462-bp. As described by McCarty et al [12],
recombinant AAV DNA of less than half of wild-type AAV
genome length can be packed as a dimer, and this double-
stranded DNA viral vector would display a rapid onset of
transgene expression.
Production and Purification of recombinant AAV2 (rAAV2)
We used the pDG helper plasmid (kindly provided by Dr.
Jurgen Kleinschmidt from DKFZ, Heidelberg, Germany)
[13], which contains AAV2 rep and cap genes plus the E2A
and E4 sequences from the adenovirus to produce the
recombinant AAV2 (rAAV2). One of the advantages of
using pDG is that no replication-competent adenovirus
has been detected. To produce rAAV2, the shuttle vector
and the helper plasmid (pDG) were co-transfected into
293 cells using the calcium phosphate-mediated transfec-
tion method (Promega). After a 48-h incubation, the cells
were harvested, pelleted down, and re-suspended in lysis
buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.5). Initially,
we used the Iodixanol density gradient centrifugation pro-
cedure as described by Zolotukhin et al. [14], followed by
purification using Heparin-Agarose Type I column
(Sigma). The rAAV2 was eluted with 5 ml 1 M NaCl inGenetic Vaccines and Therapy 2004, 2 http://www.gvt-journal.com/content/2/1/5
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PBS-MK (1 × phosphate-buffered saline, 1 mM MgCl2,
and 2.5 mM KCl). The first 2 ml elute was discarded and
the virus was collected in the subsequent 3.5 ml of the elu-
tion buffer. The virus was concentrated and desalted by
centrifugation through an Ultrafree Biomax filter unit
(Millipore). Later on, we used the single-step heparin
chromatography described by Auricchio et al. [15] to
purify the rAAV2 and scAAV2 vectors.
Quantification of rAAV2 particles
The purified viral stocks (rAAV2 vectors) were titrated to
determine the genome copies either by slot-blot hybridi-
zation [16] or by TaqMan real-time polymerase chain
reaction (PCR) (Applied Biosystems). In real-time quanti-
tative PCR, primers and probes were designed to recog-
nize the stuffer sequence of the human HPRT gene. The
primers and dual-labeled probes used and the final PCR
working concentrations were as follows:
Forward primer: 5' GCCAGGATGGTCTCCATCTC (900
nM)
Reverse primer: 5' GTGGGCCAGGCGTAGTG (900 nM)
Probe: 5' FAM-CCTCATGATCTGCCTGCTTCGGC-
TAMRA (100 nM).
FAM is fluorescein aminohexylamidite and TAMRA is
tetramethylrhodamine.
The infection potencies of rAAV vectors were evaluated by
the infectious center assay. The assay was carried out to
infect C12 cells as described by Zolotukhin et al. [17].
The titers of viral genome particle number of scAAV2 were
determined by quantitative DNA dot blot method. Each
scAAV2 particle was calculated as containing two copies of
parent AAV2 (non-modified single strand rAAV2-TTR-
RB15).
Identification of rAAV2 dimer and monomer by alkaline agarose gel 
electrophoresis
Agarose gel was cast as 0.8% in H2O; the gel was then
soaked in alkaline buffer solution (50 mM NaOH, 1 mM
EDTA) for 30 min. The viral DNA was extracted from 10
µl of purified scAAV2-TTR-RB15 viral vector in 50 µl reac-
tions containing 0.4 mg/ml proteinase K, 1% SDS, and 10
mM EDTA at 50°C for 1 h, followed by phenol/chloro-
form extraction. The DNA was precipitated with salt and
ethanol. The viral DNA was dissolved in H2O and applied
to the alkaline agarose gel. The gel was electrophoreses in
alkaline buffer for 3 h at 30 volts. At the end of gel electro-
phoresis, the gel was transferred to Hybond N+ membrane
(Amersham) overnight and hybridized with 32P-labeled
RB15 probe.
Western blot analysis
Western blot analysis was performed to detect AAV2 cap-
sid proteins (VP1, VP2, and VP3). Virus (1 × 1010 parti-
cles) was separated on 10% SDS polyacrylamide gel under
standard conditions and AAV2 capsid proteins (VP 1, VP2,
and VP3) were detected using monoclonal antibody
against AAV2 capsid proteins (American Research Prod-
ucts, Belmont, MA).
HepG2 Cells
Detection of ribozyme RB15 RNA in cells by one-step RT-PCR
A human hepatoma cell line (HepG2 cells, 2 × 105 cells)
was seeded onto each well of a six-well plate until the cells
reached 80% confluence (~5 × 105 cells). The cells were
infected with 1 × 1010 particles of rAAV-TTR-RB15 or
rAAV-TTR-RB15 mutant. At days 3 and 7 after infection,
RNA was extracted from cells using Trizol reagent (Invit-
rogen). The expression level of ribozyme RB15 RNA was
determined using the one-step RT-PCR kit (Qiagen), fol-
lowed by Southern blot analysis using the 32P-end-labeled
oligonucleotide RB15. Briefly, 1 µg of total RNA was
treated with a DNase reagent using the DNA-free kit
(Ambion) to remove the contaminating DNA. RT-PCR
was then performed in the presence of the forward primer
RBF2 (5' AGATCCACAAGCTCCTGA) and reverse primer
RBR1 (5' ATAAGCTGCAATAAACAAGT) to amplify RB15
RNA. At the same time, PCR only control experiment,
using the same amount of the treated total RNA was car-
ried out. After RT-PCR, a product of 126-bp was detected
using 1.5% agarose-1000 gel electrophoresis (Invitrogen).
The PCR product was transferred using 0.4 N NaOH, fol-
lowed by hybridization with radiolabeled oligonucleotide
RB15 to detect RB15 DNA.
Quantification of apoB mRNA levels in HepG2 cells by RNase 
Protection assay
The apoB mRNA levels in HepG2 cells after rAAV-TTR-
RB15 infection were determined using RNase protection
assay as described previously [2]. Briefly, the RNase pro-
tection assay was carried out with 10 µg of total RNA and
3 × 104  cpm of 32P-UTP-labeled antisense apoB RNA
probe in 20 µl of hybridization buffer (RPA III kit,
Ambion). After RNase digestion, the protected fragment
of 640 nucleotides was analyzed with 5% polyacrylamide-
urea gel electrophoresis and quantified using the FX phos-
phoimage system (Bio-RAD).
Animal experiments
Mice deficient in both apoB mRNA editing enzyme
(Apobec1-/-) and LDL receptor (LDLR-/-) were produced
in our laboratory [8,9] and were used for this study. This
mouse model produces apoB100 only. It has markedly
increased plasma total cholesterol and LDL cholesterol
and develops atherosclerosis on a chow diet [7-9]. Recom-
binant adeno-associated virus, rAAV2-TTR-RB15 orGenetic Vaccines and Therapy 2004, 2 http://www.gvt-journal.com/content/2/1/5
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rAAV2-TTR-RB15 mutant (as control) of 2 × 1011 virus
particles was injected into the jugular vein of 2-months-
old mice (n = 10 for each rAAV2 virus vector). These mice
were maintained on laboratory chow (4% mouse/rat diet
7001; Harlan Teklad, Madison, WI). Samples of blood or
tissue were obtained at the indicated time points after
rAAV2 vectors injection. All animal experiments were con-
ducted in accordance with the guidelines of the Animal
Protocol Review Committee of the University of Texas
Health Science Center at Houston (Houston, TX).
Analysis of DNA from tissues
Genomic DNA was prepared as described previously [18]
from mouse liver and other organs including spleen, fat,
colon, ileum, jejunum, duodenum, kidney, stomach,
lung, and heart after rAAV2 transduction. rAAV2-TTR-
RB15 or RB15-mutant genomes were determined in 1 µg
of genomic DNA by PCR using forward primer RBF2 (5'
AGATCCACAAGCTCCTGA) and reverse primer RBR1 (5'
ATAAGCTGCAATAAACAAGT) to amplify RB15 DNA in
the tissue. A product of 126-bp was detected using 1.5%
agarose-1000 gel electrophoresis (Invitrogen). The PCR
product was transferred using 0.4 N NaOH, followed by
hybridization with radiolabeled oligonucleotide RB15 to
detect RB15 DNA. Liver DNA from untreated mouse was
used as negative control.
Detection of ribozyme RB15 RNA in tissues by one-step RT-PCR
Total RNA from livers and other organs of Apobec1-/-
LDLR-/- mice was extracted using the Trizol system (Invit-
rogen). The expression levels of RB15 RNA in tissues after
treatment were detected using the one-step RT-PCR
method as described above.
Quantification of mouse apoB mRNA by real-time quantitative RT-
PCR after rAAV2-TTR-RB15 treatment
The mice apoB mRNA levels after rAAV2 transductions
were determined by real-time quantitative RT-PCR using
ABI 7700 Sequence Detection System (Applied Biosys-
tems). The sequence-specific primers and probes used for
the mouse apoB mRNA and the endogenous control 18S
ribosomal RNA were designed using Primer Express Soft-
ware (Applied Biosystems). The nucleotide sequences
were as follows:
Mouse apoB mRNA Forward primer 5' ATGTACTAATT-
GCCATAGATAGTGCCA, 
Reverse primer 5' TCGCGTATGTCTCAAGTTGAGAG, 
Probe: FAM-ATCAACTTCAATGAAAAA-MGBNFQ
Mouse 18S RNA Forward primer 5'
TAACGAACGAGACTCTGGCAT,
Reverse primer 5' CGGACATCTAAGGGCATCACAG
Probe 5' FAM-TGGCTGAACGCCACTTGTCCCTCTAA-
TAMRA.
The nucleotide sequences of each primer and probe were
Blast searched against the Genebank database to confirm
the uniqueness of each primer.
We used TaqMan One-Step RT-PCR Master Mix reagent
(Applied Biosystems) to quantify RNA as described previ-
ously [8,9]. The RNA standard curve for the specific gene
was generated from T7-cDNA plasmid vector; serial dilu-
tions of 103–109 molecules were employed in duplicate
for the assay. Total RNA was treated with DNase (DNA-
free kit; Ambion) to remove DNA contamination. The
optimum RNA concentration for each gene was deter-
mined initially using real-time quantitative RT-PCR. Each
RNA sample was then diluted accordingly. We used 150
ng and 50 pg of total RNA to quantify apoB mRNA and
18S RNA, respectively. Each of the RNA samples was nor-
malized with an endogenous control of 18S ribosomal
RNA. The copy numbers were calculated from the stand-
ard curve. The results are expressed as the ratio of specific
mRNA/18S RNA.
Quantification of atherosclerotic lesions
The mice were anesthetized, exsanguinated and the aorta
was carefully excised with part of the heart still attached.
Under the stereomicroscope (Leica MZ60), all the fat and
adventitious tissues were removed. With the major
branching vessels still attached, the aorta was opened lon-
gitudinally from the iliac bifurcation to the aortic arch,
and all the branching vessels and the heart were then
removed [8,9]. The aorta was pinned flat on a white wax
surface, fixed overnight in 10% (v/v) formalin and stained
with freshly prepared, filtered Oil Red O solution [19].
The aorta was scanned using the Polaroid Sprint Scan 35
Plus with Geoscan Enabler, the image was captured using
Adobe Photoshop 5.0, and the background was removed
with the guidance of the stereomicroscope. The total areas
of the aorta and the atherosclerotic plaques were quanti-
fied using SigmaScan Pro 4.0 imaging software (SPSS Sci-
ence, Chicago, IL). The results were presented as the
percentage of the aortic surface covered by lesions (mm2)
divided by the total surface area of the aorta (mm2).
Other Assays
Plasma cholesterol and triglyceride levels were deter-
mined using commercial enzymatic assay kits (Sigma).
Immunoblot analysis, as described previously [20], was
used to detect mouse apoB. Mouse apoB-specific antise-
rum was kindly provided by Dr. Thomas Innerarity (Glad-
stone Institute, San Francisco, CA).Genetic Vaccines and Therapy 2004, 2 http://www.gvt-journal.com/content/2/1/5
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Statistical analysis
The results are expressed as means ± SD. Student t-test was
used to evaluate differences between the two groups. The
p < 0.05 was considered to be significantly different.
Results and Discussion
We have previously demonstrated that hammerhead
ribozyme RB15 cleaves both human and mouse apoB
mRNA efficiently [3]. In this study, we constructed a
recombinant adeno-associated virus vector expressing
hammerhead ribozyme RB15 driven by a liver-specific
promoter TTR (rAAV2-TTR-RB15). This rAAV2-TTR-RB15
vector was used to demonstrate the effects of long-term
gene expression of ribozyme RB15 in mice on the altera-
tion of apoB mRNA levels and the progression of
atherosclerosis.
Characterization of the purified rAAV2-TTR-RB15
The genome copies of the purified rAAV2 virus were meas-
ured by real-time quantitative PCR. The purity of each
viral vector prepared using either an iodixanol density gra-
dient centrifugation followed by heparin-agarose column
or a single-step heparin chromatography was examined by
10% SDS/PAGE. A representative preparation of rAAV2 by
a single-step heparin chromatography method was shown
in Fig. 1A and 1B. The structural CAP proteins of the
rAAV2 vector (VP1, VP2, and VP3) were detected by
Coomassive blue staining (Fig. 1A). The Western blot
analysis using a mouse monoclonal antibody against the
AAV2 capsid proteins confirmed that VP1, VP2, and VP3
were AAV2 structural proteins (Fig. 1B).
Effect of adeno-associated virus-mediated Ribozyme RB15 
(rAAV2-TTR-RB15) gene expression in HepG2 cells
To test if the recombinant rAAV2-TTR-RB15 vector would
result in a decrease of apoB mRNA levels, we infected
HepG2 cells with rAAV2-TTR-RB15 or rAAV2-TTR-RB15-
mutant to confirm that the expressed RB15 was biologi-
cally active. Total RNA was extracted from cells at days 3
and 7 after infection, RB15 RNA expression was deter-
mined by RT-PCR, followed by Southern blot analysis. As
shown in Fig 2A, RB15 RNA was detected by RT-PCR and
Southern blot analysis at days 3 and 7 after infection.
There was no detectable band in the corresponding sam-
ples analyzed by PCR only.
We used the RNase protection assay to quantify apoB
mRNA concentration after rAAV2 infection. As shown in
Fig. 2B, a protected fragment of 640 nucleotides was
detected in non-treated cells and cells treated with either
the rAAV2-TTR-RB15 or the rAAV2-TTR-RB15-mutant.
The levels of apoB mRNA was normalized with GAPDH
transcripts. In comparison to non-treated cells, at day-3
after infection, apoB mRNA levels were decreased 17%
(non-treated = 0.813 ± 0.08, n = 3; rAAV-TTR-RB15-
treated = 0.672 ± 0.117, n = 3; p = 0.0849). By day-7 the
apoB mRNA levels were significantly decreased 91.5%
(rAAV-TTR-RB15-treated = 0.069 ± 0.0, n = 3; p = 0.0019).
In contrast, the apoB mRNA levels in cells treated with
rAAV2-TTR-RB15-mutant (control vector) did not vary
significantly; there was an enhancement at day-3 after
infection of RB15 mutant vector, when compared to non-
treated cells (non-treated = 0.861 ± 0.055, rAAV-TTR-
RB15-mutant at day-3 = 1.102 ± 0.174, n = 3, p = 0.0643;
day-7 = 0.947 ± 0.053, n = 3, p = 0.0613). Therefore, the
AAV2-mediated apoB mRNA-specific hammerhead
ribozyme RB15 markedly reduced apoB mRNA transcripts
in HepG2 cells only at day-7 after treatment.
Hepatic uptake and expression of rAAV2-TTR-RB15 in 
mouse liver
Next, we injected rAAV2-TTR-RB15 or rAAV2-TTR-RB15-
mutant (2 × 1011 particles) via the jugular vein into LDb
mice (LDLR-/-Apobec1-/-) to examine the persistence of
the RB15 gene expression and the specificity of the TTR
promoter. Organs including liver, spleen, kidney, heart,
lung, duodenum, jejunum, ileum, colon, fat, and muscle
were collected at days 7 and 150 after virus injection. The
DNA of the rAAV vector was detected mostly in the liver
(95%) with trace amounts in the spleen (3.5%) and kid-
ney (1%) at day-7 after injection. At day-150 after injec-
tion, vector DNA was still readily detectable in the liver
with trace amounts in the kidney (Fig. 3A). In contrast,
The purified rAAV-TTR-RB15 vector Figure 1
The purified rAAV-TTR-RB15 vector. The purified rAAV-
TTR-RB15 prepared by a single-step heparin chromatogra-
phy was separated by 10% SDS-PAGE, stained with 
Coomassieve blue (A), and the AAV capsid proteins (VP1, 
VP2, and VP3) were detected with a monoclonal antibody 
(B). The molecular weights of the capsid proteins are shown.
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The expressed ribozyme RB15 in HepG2 cells Figure 2
The expressed ribozyme RB15 in HepG2 cells. HepG2 cells (5 × 105 cells/well) were infected with rAAV-TTR-RB15 (1 × 1010 
particles/well). (A). Total RNA was extracted from infected cells at days 3 (lane 2) and 7 (lane 3). Ribozyme RB15 RNA was 
detected using RT-PCR, followed by Southern blot analysis. Lane 1 is non-infected control RNA and lane 4 is H2O blank. For a 
negative control, the same experiment was performed also by PCR only. The DNA marker is 100-bp DNA ladder. The same 
experiment was carried out with the rAAV-TTR-RB15 mutant. The results are not shown here. (B). Total RNA (10 µg) was 
hybridized with 32P-UTP-labeled anti-apoB RNA and 32P-UTP-labeled anti-GAPDH RNA. The expression levels of apoB mRNA 
and GAPDH mRNA were determined by an RNase protection assay using an RPA III kit. After RNase digestion, the protected 
fragments (apoB RNA = 640 nt and GAPDH RNA = 316 nt) were generated and analyzed with 5% polyacrylamide gel electro-
phoresis. The concentrations of protected RNAs were determined by a Phosphoimager FX system (Bio-Rad). The levels of 
apoB RNA were normalized with GAPDH RNA and a representative experiment is shown here. The probes and protected 
fragments of apoB mRNA and GAPDH RNA are indicated.
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The effect of rAAV2-TTR-RB15-mediated gene expression in LDLR-/-Apobec1-/- mice Figure 3
The effect of rAAV2-TTR-RB15-mediated gene expression in LDLR-/-Apobec1-/- mice. (A). The DNAs from various organs were 
extracted at days 7 and 150 after rAAV2-TTR-RB15 transduction. The AAV2-RB15 DNA was detected by amplification using 
PCR, followed by Southern blot analysis. The radioactive bands of RB15 are shown. (B). The expressed ribozymes RB15 and 
RB15 mutant RNAs in the livers of LDLR-/-Apobec1-/- mice treated with rAAV2-TTR-RB15 or RB15-mutant. The total liver 
RNA was extracted from each mouse at day-150 after rAAV-TTR-RB15 (2 × 1011 particles/animal, samples 1 – 5) or rAAV-
TTR-RB15 mutant (2 × 1011 particles/animal, samples 6 – 10) transduction. Ribozymes RB15 or RB15 mutant RNAs were 
detected using RT-PCR, followed by Southern blot analysis. The radioactive bands of ribozymes RB15 and RB15 mutant are 
shown. The same samples were also subjected to PCR only, followed by Southern blot analysis. There were no detectable 
bands in these samples. (C). The effect of ribozymes RB15 and RB15 treatment on mouse apoB mRNA levels. Mouse apoB 
mRNA and endogenous 18S RNA from each mouse liver at day-150 after rAAV-TTR-RB15 or RB15 mutant treatment were 
determined by real-time quantitative RT-PCR. The results are expressed as the ratio of mouse apoB mRNA (mApoB mRNA) 
to 18S RNA. The results are shown as means ± standard deviation of ten animals. Each assay was performed in duplicate at 
two separate times. The results were analyzed by Student t-test.
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using RT-PCR method the ribozyme RNAs of RB15 and
RB15 mutant were detected only in the mouse liver, but
not in any other tissues that collected either at day-7 or at
day-150 after injection (data not shown).
Fig. 3B shows the results of ribozyme RB15 RNAs ana-
lyzed by RT-PCR in the livers of mice treated with rAAV2-
TTR-RB15 (numbers 1 to 5) and rAAV2-TTR-RB15 mutant
(numbers 6 to 10) at day-150 after injection. Control
experiments using the same RNA samples analyzed by
PCR only did not detect any RB15 RNA (Fig. 3B). There-
fore, our results demonstrate that the gene expression of
ribozyme RB15 persisted to day-150 (5 months) after
virus injection and ribozyme RB15 was specifically
expressed in the liver.
We, then, used real-time quantitative RT-PCR to examined
the effect of rAAV2-TTR-RB15 and rAAV2-TTR-RB15-
mutant on the levels of mouse apoB mRNA at day-150
after transduction. As shown in Fig. 3C, mouse apoB
mRNA was significantly decreased 43% after RB15 treat-
ment (p  = 0.0262), compared to RB15-mutant treated
group.
However, unlike the results observed in our previous
experiments using adenovirus-mediated RB15, the per-
sistent but low levels expression of RB15 ribozyme RNA
did not have effects on the levels of plasma cholesterol
(day-0 to day-150; 357 ± 42 to 435 ± 35 mg/dl) or triglyc-
erides (day-0 to day-150; 237 ± 137 to 253 ± 15 mg/dl).
The mouse plasma apoB levels also remained relatively
the same throughout the study. We quantified the extent
of atherosclerotic lesions on each animal after treatment.
There was no difference in the severity of atherosclerotic
lesions when comparing rAAV2-TTR-RB15-treated ani-
mals to rAAV2-TTR-RB15-mutant-control animals
(rAAV2-TTR-RB15-treated = 11.9 ± 4.02 % lesions, rAAV2-
TTR-RB15-mutant-treated = 11.6 ± 2.10 % lesions).
Taken together, rAAV2-mediated ribozyme gene expres-
sion in LDb  (LDLR-/-Apobec1-/-) mice expressed active
RB15 RNA, which decreased apoB mRNA by 43%. Never-
theless, this reduction levels of apoB mRNA did not yield
a result of lowering the levels of apoB proteins or plasma
cholesterol or triglyceride. Our previous works of express-
ing ribozyme RB15 mediated by an adenovirus vector in
Apobec1-/-ERhB+/+ mice decrease apoB mRNA levels by
80%, which produce a markedly reduction of apoB pro-
tein of 62% and cholesterol and triglyceride of 42% and
51%, respectively [3]. The different observations demon-
strated in our studies between using an adenovirus vector
and an adeno-associated vector were a great concern.
AAV2 has been shown to have limit ability to transduce
hepatocytes [21]. This low transduction ability of AAV2 to
hepatocytes may be one of the main reasons that the
expressed active RB15 RNA was limited to cleave apoB
mRNA to a small percentage of cells. We have shown that
apoB mRNA is constitutively expressed in hepatocytes
[22] and the region of ribozyme RB15 target site GUA6679
is AU-rich, which was predicted to have a kinetic advan-
tage for success in cleaving the transcript [2]. Thus, it is
possible that the highly efficient RB15 catalytic RNA
cleaved apoB mRNA in a limited number of transduced
cells to yield a 43% reduction of apoB mRNA levels, but
without a significant influence on the levels of apoB pro-
teins or the lipids. Furthermore, LDb (LDLR-/-Apobec1-/-)
mice have very high levels of cholesterol and triglyceride
and the mice secrete cholesterol and triglyceride-rich LDL
[9], therefore, we think a very efficient AAV gene transduc-
tion vector is probably needed to accomplish the goal of
regulating the apoB production.
Improved AAV-mediated gene expression strategies
Ferrari et al. [23] have suggested that second-strand syn-
thesis is a rate-limiting step for transduction of therapeu-
tic genes by the AAV vectors. It was shown that the
conversion of the input single-stranded DNA vector into a
double-stranded DNA template for transcription is a slow
and inefficient process in most non-dividing cells includ-
ing hepatocytes. To enhance the transduction in vivo,
McCarty et al [12] have shown that generation of a self-
complementary AAV (scAAV) would bypass the rate-lim-
iting step of second-strand synthesis. Ribozyme RB15 has
a size of 61-bp in length, which is an ideal molecule for
this approach. Accordingly, our laboratory has con-
structed the scAAV2 vectors expressing active ribozyme
RB15 and inactive ribozyme RB15-mutant (Fig. 4A,
scAAV2-TTR-RB15 or -RB15-mutant).
As shown in Fig. 4B, ~40% of AAV vectors produced were
scAAV2-TTR-RB15 vector containing dimeric DNA
genomes of 4856 nucleotides as analyzed by alkaline aga-
rose gel electrophoresis. We used these scAAV2-TTR-RB15
and -RB15 mutant vectors to infect HepG2 cells, on days
1 and 3 after infection; scAAV-TTR-RB15 vector expressed
much more ribozyme RB15 RNA, > 3-fold more ribozyme
RNA produced compared to the non-modified parent
RB15 vector (Fig. 4C) as determined by semi-quantitative
RT-PCR. Moreover, on day-3 after infection, the apoB
mRNA levels (determined by real-time RT-PCR, Fig. 4D)
were significantly decreased 47% in scAAV-TTR-RB15
treated cells (p = 0.001), when compared to cells treated
with inactive scAAV-TTR-RB15-mutant. In contrast, the
apoB mRNA levels remained the same on cells treated
with non-modified parent rAAV2-TTR-RB15 vector.
Therefore, our results show that scAAV vector bypassed
the conversion of single-stranded DNA to double-
stranded DNA process, expressed ribozyme RB15 RNA
faster and more efficiently.Genetic Vaccines and Therapy 2004, 2 http://www.gvt-journal.com/content/2/1/5
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The expression of self-complementary AAV2-TTR-RB15 (scAAV2-TTR-RB15) vector in HepG2 cells Figure 4
The expression of self-complementary AAV2-TTR-RB15 (scAAV2-TTR-RB15) vector in HepG2 cells. (A). The drawings depict 
the predicted conformations of monomer and dimer of TTR-RB15 virions. (B). Alkaline agarose gel electrophoresis (0.8%) of 
scAAV2-TTR-RB15 viral DNA, followed by Southern blot analysis, hybridized with 32P-labeled RB15 probe. The positions of 
monomer and dimmer are shown. (C). Comparison of the ribozyme RB15 RNA levels between cells treated with non-modi-
fied parent rAAV2-TTR-RB15 vectors and cells treated with scAAV2-TTR-RB15 vectors at days 1 and 3 after treatment. Total 
RNA was extracted from HepG2 cells treated with either non-modified parent AAV2-TTR-RB15 or scAAV2-TTR-RB15 vec-
tors. The levels of RB15 RNA were determined using one-step RT-PCR and analyzed by 2% agarose gel electrophoresis. The 
same samples were also determined by PCR only. The position of RB15 RNA is shown. (D). Comparison of apoB mRNA levels 
in HepG2 cells at day-3 after treatment with non-modified parent rAAV2-TTR-RB15 vectors or with modified scAAV2-TTR-
RB15 vectors. ApoB mRNA was determined by real-time quantitative RT-PCR. The apoB mRNA levels were normalized with 
18S RNA. The results are expressed as % of cells treated with inactive RB15-mutant. The results are shown as means ± stand-
ard deviation of triple experiments. Experiment of cells infected with adenovirus-RB15-mutant, adenovirus-RB15 (positive con-
trol) are performed at the same time and used as a positive comparison purpose. Cells treated with parent-rAAV2-TTR-RB15-
mutant, parent rAAV2-TTR-RB15, scAAV2-TTR-RB15-mutant, and scAAV2-TTR-RB15 are shown. The p values analyzed by 
student t-test are shown. ns = not significant
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Recently, two groups [24,25] using double strand scAAV2
vector expressed GFP in mouse brain and liver. They
showed that scAAV2 increased transgene expression faster,
more efficiently, and last longer, when compared with
non-modified single strand AAV2. Wang et al [25] showed
that scAAV in liver remained as the circular low molecular
weight episomal DNA, which gave the steady-state levels
of transgene expression. From our experience shown on
this study of using single-stranded rAAV2-TTR-RB15 vec-
tor in mice, we knew it is necessary to generate an optimal
vector to obtain successful results in vivo. Wang et al. [25]
and McCarty et al. [24] have shown that a modified
scAAV2 vector by removing the D-sequence in the termi-
nal resolution site of AAV2-5' ITR region [24,25] yield
high percentage of double-strand DNA and produce rapid
and highly efficient transduction in mice. Furthermore,
AAV2/8 vector has been shown to be more effective in
transducing hepatocytes [26-28]. Thus, our laboratory are
in the process of improving the scAAV vector by using the
modified scAAV vector that produce mainly double-
stranded DNA and package it in an AAV2/8 vector. These
improvements should generate a much better AAV vector
to express ribozyme RB15 in the liver in mice. We expect
this improved AAV vector would provide a much better
outcome than we have demonstrated using non-modified
AAV2 and adenovirus vectors. The markedly reduction of
apoB mRNA levels would lead to the inhibition of the
development of atherosclerotic lesions.
The recent discovery of using short interfering RNA
(siRNA) species to silence gene expression has demon-
strated its great potential as a therapeutic-based gene
silencing. Both ribozyme and siRNA are RNA-based tech-
nologies. Ribozymes are catalytic RNAs, which cleaves the
target sequences efficiently. siRNAs are short RNAs of 21–
23 nucleotides in length and are incorporated into a
nuclease complex, the RNA-induced silencing complex
(RISC), which then targets and cleaves the mRNA. The fac-
tors influencing efficient gene target of ribozyme and
siRNA are similar, including position of the binding site,
secondary and tertiary structures in mRNA, base pairing of
RNA, cleavage efficiency to the mRNA, and turnover of
mRNA after cleavage. Ribozyme technology has been
shown to have some difficulties to apply universally,
although apoB mRNA-specific hammerhead ribozyme
cleaves apoB mRNA efficiently. The applicability of siRNA
in mammals is probably limited also, since the introduc-
tion of dsRNA longer than 30 nucleotides induces a
sequence-nonspecific interferon response [29] and the
induction of gene activation of siRNA appears to be tran-
sient. However, using synthetic 21 nucleotides targeted
specific to gene Fas in mice down-regulated Fas mRNA
and prevented liver injury [30]. Thus, RNAi provides the
opportunity to be an exciting new therapeutic approach.
Allude to all; the development of a suitable long-term
gene transfer vector will benefit to deliver all of these mol-
ecules to cells to regulate gene expression.
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